Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its ...

Bristol Myers Squibb is acquiring 2seventy bio ... Graybosch noted that 2seventy CEO Chip Baird stated at an investor conference last week that his company’s move toward profitability makes ...